1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

UroGen Approaches A Big Expansion In Bladder Cancer

 
• By Jessica Merrill

The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.

edge
UroGen is on the edge of a new growth phase • Source: Shutterstock

UroGen Pharma, Ltd. is getting closer to a goal it has worked towards for many years, launching UGN-102, an intravesical mitomycin-based solution, for the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMIBC), a potentially transformative indication for the company given the market size. CEO Liz Barrett talked to Scrip in an interview about the regulatory developments and launch preparations for UGN-102.

Key Takeaways
  • UroGen plans to finalize a rolling NDA for UGN-102 in bladder cancer in September.

“The company was initially built off the opportunity in bladder cancer,” Barrett said. “We’re finally kind of where we were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

More from Therapy Areas